Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ)
CNY 17.41
(0.58%)
CNY 17.41
(0.58%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -43.9 Million | -48.69 Million | -262.23 Million | 622.18 Million | 427.83 Million | 78.57 Million |
| Net Income | 27.35 Million | -118.95 Million | 204.67 Million | 667.06 Million | 585.72 Million | 163.66 Million |
| Depreciation & Amortization | 305.12 Million | 254.93 Million | 193.41 Million | 136.09 Million | 101.17 Million | 82.79 Million |
| Deferred income taxes | -280.1 Thousand | -5.29 Million | 1.06 Million | 5.65 Million | 3.97 Million | -2.17 Million |
| Stock-based compensation | -34.67 Million | -1.91 Million | 30.57 Million | 6.87 Million | 12.68 Million | 9.12 Million |
| Change in working capital | -595.84 Million | -339.68 Million | -722.01 Million | -185.73 Million | -308.69 Million | -222.34 Million |
| Other non-cash items | 42.8 Million | 154.99 Million | 61.69 Million | 4.75 Million | 49.63 Million | 54.46 Million |
| Investing Cash Flow | -355.35 Million | -520.81 Million | -802.37 Million | -517.3 Million | -159.69 Million | -91.46 Million |
| Investments in PPE | -316.8 Million | -527.01 Million | -736.38 Million | -506.05 Million | -354.1 Million | -179.88 Million |
| Acquisitions | 3.9 Million | 4.11 Million | -5.64 Million | -37.69 Million | -8.36 Million | -6 Million |
| Investment purchases | -7.5 Million | -25.5 Million | -70.7 Million | -10.67 Million | 867.32 Thousand | 164.2 Thousand |
| Sales/Maturities of investments | 10 Million | 388.67 Thousand | 67.83 Million | 45.55 Million | 5.07 Million | 13.79 Million |
| Other Investing Activities | -34.6 Million | 27.19 Million | -57.47 Million | -8.42 Million | 196.83 Million | 80.46 Million |
| Financing Cash Flow | 363.35 Million | 519.34 Million | 229.66 Million | 1.01 Billion | -468.73 Million | 142.66 Million |
| Debt repayment | -504.78 Million | -752.92 Million | -489.25 Million | -255.59 Million | -810.07 Million | -587.58 Million |
| Dividends payments | -51.11 Million | -34.79 Million | -96.65 Million | -91.09 Million | -27.33 Million | -36.6 Million |
| Common Stock Repurchased | - | -58 Million | -237.36 Thousand | - | -449.18 Thousand | - |
| Common Stock Issuance | - | 58 Million | 237.36 Thousand | - | 3.33 Million | 34.18 Million |
| Other Financing Activities | -90.31 Million | 1.34 Billion | 831.35 Million | 1.36 Billion | 378.1 Million | 766.85 Million |
| Accounts receivables | -242.67 Million | -269.46 Million | -315.07 Million | -326.32 Million | -82.4 Million | -186.87 Million |
| Accounts payables | -340.17 Million | 450.23 Million | 355.45 Million | 275.11 Million | 53.27 Million | 122.73 Million |
| Inventory | -12.71 Million | -515.15 Million | -763.46 Million | -140.18 Million | -283.54 Million | -156.02 Million |
| Other working capital | -34.67 Million | -5.29 Million | 1.06 Million | 5.65 Million | 3.97 Million | -66.32 Million |
| Cash at beginning of period | 270.22 Million | 307.47 Million | 1.14 Billion | 53.7 Million | 250.32 Million | 116.83 Million |
| Cash at end of period | 232.43 Million | 270.22 Million | 307.47 Million | 1.14 Billion | 53.7 Million | 250.32 Million |
| Capital Expenditure | -316.8 Million | -527.01 Million | -736.38 Million | -506.05 Million | -354.1 Million | -179.88 Million |
| Effect of forex changes on cash | -1.89 Million | 12.93 Million | -6.14 Million | -20.52 Million | 3.97 Million | 3.71 Million |
| Net cash flow / Change in cash | -37.79 Million | -37.24 Million | -841.08 Million | 1.09 Billion | -196.62 Million | 133.48 Million |
| Free Cash Flow | -360.71 Million | -575.71 Million | -998.61 Million | 116.12 Million | 73.73 Million | -101.31 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 31.89 Million | 12.69 Million | 40.51 Million | 27.35 Million | -41.43 Million | 683.02 Thousand |
| Depreciation & Amortization | - | 82.12 Million | 82.12 Million | 305.12 Million | 79.51 Million | 79.51 Million |
| Deferred income taxes | - | - | - | -280.1 Thousand | - | - |
| Stock-based compensation | - | - | - | -34.67 Million | -34.67 Million | - |
| Change in working capital | - | - | - | -595.84 Million | -290.06 Million | - |
| Other non-cash items | -1.33 Million | 272.06 Million | 58.52 Million | 42.8 Million | 213.27 Million | -86.68 Million |
| Investing Cash Flow | -56.61 Million | -47.65 Million | -63.27 Million | -355.35 Million | -87.32 Million | -42.18 Million |
| Investments in PPE | -33.27 Million | -35.37 Million | -39.71 Million | -316.8 Million | -78.16 Million | -26.56 Million |
| Acquisitions | 346.51 Thousand | 303.93 Thousand | 318.38 Thousand | 3.9 Million | 2.13 Million | 871.7 Thousand |
| Investment purchases | -26.55 Million | - | - | -7.5 Million | - | -500 Thousand |
| Sales/Maturities of investments | 77.7 Thousand | 154.4 Thousand | 36 Thousand | 10 Million | 5 Million | 2.04 Million |
| Other Investing Activities | 3.13 Million | -12.58 Million | -23.87 Million | -34.6 Million | -5.08 Million | -18.03 Million |
| Financing Cash Flow | 97.07 Million | -142.55 Million | -42.69 Million | 363.35 Million | -65.23 Million | 140.92 Million |
| Debt repayment | -115.91 Million | -121.66 Million | -80.01 Million | -504.78 Million | -30.99 Million | -605.07 Million |
| Dividends payments | -16.71 Million | -28.43 Million | -14.68 Million | -51.11 Million | -15.76 Million | -13.77 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -2.13 Million | -15.39 Million | 37.31 Million | -90.31 Million | -80.47 Million | 759.76 Million |
| Accounts receivables | - | - | - | -242.67 Million | -242.67 Million | - |
| Accounts payables | - | - | - | -340.17 Million | - | - |
| Inventory | - | - | - | -12.71 Million | -12.71 Million | - |
| Other working capital | - | - | - | -34.67 Million | -34.67 Million | - |
| Cash at beginning of period | 251.28 Million | 357.34 Million | 434.05 Million | 270.22 Million | 298.32 Million | 283.34 Million |
| Cash at end of period | 319.82 Million | 424.7 Million | 357.34 Million | 232.43 Million | 232.43 Million | 298.32 Million |
| Capital Expenditure | -33.27 Million | -35.37 Million | -39.71 Million | -316.8 Million | -78.16 Million | -26.56 Million |
| Effect of forex changes on cash | -2.4 Million | 8.39 Million | 4.97 Million | -1.89 Million | -6.5 Million | 2.29 Million |
| Net cash flow / Change in cash | 68.53 Million | 67.36 Million | -76.7 Million | -37.79 Million | -65.88 Million | 14.98 Million |
| Free Cash Flow | -2.71 Million | 167.25 Million | 59.32 Million | -360.71 Million | 14.15 Million | -112.56 Million |
3652
688318
HGH
CLEN
AMPG
IEM